Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc.AMRX · Entity 820 | SVP, Chief Legal Officer | January 03, 2020 | January 06, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amneal Pharmaceuticals, Inc.
Report date January 03, 2020 · Filed January 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 20,426 |
Ending reported balance
After 2020-01-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-01-03 · Exercise / conversion · Acquired 27,614 · Balance 28,614 F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Row 2 · 2020-01-03 · Tax withholding · Disposed 8,188 · Balance 20,426 F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 82,843 |
Reported balance
After 2020-01-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-01-03 · Exercise / conversion · Disposed 27,614 · Balance 82,843 F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4: On January 3, 2019, the reporting person was granted 110,457 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock.
F3: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units.
F4: On January 3, 2019, the reporting person was granted 110,457 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2020 Filed Jan 6, 2020 22:20 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionRestricted Stock Units · Derivative | 27,614 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-20-000002 · wf-form4_157834922391058.xml · derivative · entry 3 BUCHEN DAVID A · CIK 0001241751 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,843 Underlying: Class A Common Stock · 27,614 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F4 · derivative.exercise_date: On January 3, 2019, the reporting person was granted 110,457 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. F4 · derivative.expiration_date: On January 3, 2019, the reporting person was granted 110,457 restricted stock units, vesting in four equal installments beginning on the first anniversary of the grant date. The restricted stock units do not expire. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 22:20 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Tax withholdingClass A Common Stock | 8,188 | $4.72 | $38,647.36 |
DisclosureSEC source: 0001723128-20-000002 · wf-form4_157834922391058.xml · nonDerivative · entry 2 BUCHEN DAVID A · CIK 0001241751 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,426 F3 · shares: Represents shares of common stock withheld to satisfy tax withholding obligations relating to the vesting of restricted stock units. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 22:20 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | Exercise / conversionClass A Common Stock | 27,614 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001723128-20-000002 · wf-form4_157834922391058.xml · nonDerivative · entry 1 BUCHEN DAVID A · CIK 0001241751 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,614 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the gross number of shares of common stock awarded to the reporting person in connection with the vesting of restricted stock units. The actual number of shares issued was reduced by the number of shares withheld to satisfy tax withholding obligations. See footnote 3. F2 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 22:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantRestricted Stock Units · Derivative | 110,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001723128-19-000009 · wf-form4_154690177391907.xml · derivative · entry 2 BUCHEN DAVID A · CIK 0001241751 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,457 Underlying: Class A Common Stock · 110,457 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning on January 3, 2020 and have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning on January 3, 2020 and have no expiration date. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 22:56 UTC | Amneal Pharmaceuticals, Inc. AMRX · Entity 820 | GrantStock Option · Derivative | 227,273 | $0.00 Strike: $13.58 | $0.00 |
DisclosureSEC source: 0001723128-19-000009 · wf-form4_154690177391907.xml · derivative · entry 1 BUCHEN DAVID A · CIK 0001241751 · SVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,273 Underlying: Class A Common Stock · 227,273 shares Expires 2029-01-03 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on January 3, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.